- Home
- TCBS vs OTLK Comparison
TCBS vs OTLK Comparison
Compare TCBS & OTLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TCBS
- OTLK
- Stock Information
- Founded
- TCBS 1934
- OTLK 2010
- Country
- TCBS United States
- OTLK United States
- Employees
- TCBS N/A
- OTLK N/A
- Industry
- TCBS Banks
- OTLK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TCBS Finance
- OTLK Health Care
- Exchange
- TCBS Nasdaq
- OTLK Nasdaq
- Market Cap
- TCBS 48.7M
- OTLK 42.8M
- IPO Year
- TCBS N/A
- OTLK 2016
- Fundamental
- Price
- TCBS $16.11
- OTLK $1.15
- Analyst Decision
- TCBS
- OTLK Buy
- Analyst Count
- TCBS 0
- OTLK 5
- Target Price
- TCBS N/A
- OTLK $5.25
- AVG Volume (30 Days)
- TCBS 4.3K
- OTLK 2.7M
- Earning Date
- TCBS 11-12-2025
- OTLK 08-14-2025
- Dividend Yield
- TCBS 0.99%
- OTLK N/A
- EPS Growth
- TCBS N/A
- OTLK N/A
- EPS
- TCBS 0.80
- OTLK N/A
- Revenue
- TCBS $14,831,000.00
- OTLK $1,505,322.00
- Revenue This Year
- TCBS N/A
- OTLK N/A
- Revenue Next Year
- TCBS N/A
- OTLK $343.94
- P/E Ratio
- TCBS $20.23
- OTLK N/A
- Revenue Growth
- TCBS 51.57
- OTLK N/A
- 52 Week Low
- TCBS $14.79
- OTLK $0.79
- 52 Week High
- TCBS $19.40
- OTLK $6.98
- Technical
- Relative Strength Index (RSI)
- TCBS 47.36
- OTLK 46.22
- Support Level
- TCBS $16.10
- OTLK $1.04
- Resistance Level
- TCBS $16.23
- OTLK $1.13
- Average True Range (ATR)
- TCBS 0.19
- OTLK 0.07
- MACD
- TCBS -0.04
- OTLK 0.05
- Stochastic Oscillator
- TCBS 5.40
- OTLK 84.91
About TCBS Texas Community Bancshares Inc.
Texas Community Bancshares Inc is a holding company. The company's business consists of taking deposits from the general public and investing those deposits, together with funds generated from operations and borrowings from the Federal Home Loan Bank of Dallas, in residential real estate loans and commercial real estate loans and, to a lesser extent, commercial loans, construction and land loans, and consumer and other loans. Its portfolio segments are real estate, agriculture, commercial, consumer and other.
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.